137 related articles for article (PubMed ID: 37856412)
1. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
3. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.
Casarini AP; Jallad RS; Pinto EM; Soares IC; Nonogaki S; Giannella-Neto D; Musolino NR; Alves VA; Bronstein MD
Pituitary; 2009; 12(4):297-303. PubMed ID: 19330452
[TBL] [Abstract][Full Text] [Related]
5. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly.
Gatto F; Biermasz NR; Feelders RA; Kros JM; Dogan F; van der Lely AJ; Neggers SJ; Lamberts SW; Pereira AM; Ferone D; Hofland LJ
Eur J Endocrinol; 2016 May; 174(5):651-62. PubMed ID: 26888629
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
7. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
8. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
9. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
10. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
[TBL] [Abstract][Full Text] [Related]
12. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
15. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
17. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
18. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
19. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
